$NXAMD Becomes a Publicly Traded Company

Consideration for the sale and purchase of the Sellers Assets shall be in the form of financing commitment, shares of the Corporation as well as other items as set forth herein and as follows (collectively the “Consideration”):

a. A purchase price paid for by the issuance of 57,105,263 shares of Common stock, par value $0.001, on the Closing Date to CB Scientific shareholders. All such common shares shall be received of the NXAM common shares under the requisite restriction of Rule 144 of the Securities Act.

b. NXAM shall also issue to CB One share of Preferred Series A2 of NXAM with a thirty percent (30%) dividend of the yearly gross cash flow of the operations of CB. Such share shall not be sold or delivered to any party except for CB as a corporation. The rights to the dividend of revenue shall be designated by CB within thirty days of the execution of this agreement. Future revenue distribution shall be subject to separate agreement. CB will also receive thirty percent (30%) dividend of the yearly gross cash flow of any other operations, projects (Labs, schools, etc.) delivered by CB to the Company.

c. CB shall with execution of this agreement be entitled to 25,000,000 shares of the common stock warrant of NXAM with the price for such warrant exercise being based on a 50% discount to the closing price of the stock on the date of execution of this agreement (post reverse capitalization). Such warrants shall be exercisable for a period of two years from the date of this agreement.

CB Scientific is the second spin-off from the parent company, FutureWorld Corp (OTC PINK: FWDG). FutureWorld will be providing dividend to its shareholders of the sale of CB Scientific in coming weeks.

CB Scientific, has concluded three months of R&D, design and manufacturing of the next generation THC and CBD detection kits with ISO lab certified seal of approval. The new generation of the test kits are unveiled under PersonalAnalytics “Test4” line of products, consisting of superior testing platform and lab tested seal of approval. New version of the PersonalAnalytics includes; Test4 CBD, Test4 THC & Test4 Combo (both THC & CBD) and Test4 Edibles. Test4 Hemp will be introduces next.

The Test4 line of products will be sold globally through major distributors and retail through Company’s website. You can order your kits online at; https://www.test4thc.com.

CB Scientific’s PersonalAnalytics are the first tests for consumers that are available for personal use to test for cannabinoids, including THC and CBD, outside of a lab setting. These affordable and high-quality tests provide results in ten minutes or less, and have numerous uses for recreational and medical purposes, including patients who need to use medical cannabis and hemp-related products such as CBD oil.

The tests have been featured on ABC, CBS, Fox, Telemundo, The Adam Dunn Show, as well as in publications such as High Times, Culture and Forbes Magazine. In December 2014, just 94 days after its launch the THC & CBD Test Kits were awarded “Product of the Year” by the Cannabis Business Awards in Colorado.

About CB Scientific

CB Scientific (www.cbscientific.com), based in Denver, Colorado, through its subsidiaries, designs, develops and manufactures Life Science Analytical Tools and Devices, laboratory services, personal analytical kits and devises and CBD hemp oil and nutraceutical formulations for growers, care takers, dispensaries and companies worldwide. CB Scientific is continuing to develop new technologies specifically for cannabis (hemp) analytics. CB Scientific believes every product sold to patients as “Medical Quality” should be inspected for health benefits, safety, consistency, purity, potency and packaged properly for distribution. CB Scientific has worked with many of the cannabis industry leaders in the country and have also been featured in cannabis industry publications including High Times Magazine, Culture and many trade publications, on-air interviews and panel discussions across the United States. CB Scientific’s focus has been the education and safety of consumers combined with innovation to put power into the hands of the patients.

To request further information about CB Scientific, please email us at info@cbscientific.com, log onto our website at https://www.cbscientific.com or visit us on Twitter @cbscientific.

About FutureWorld Corp.

FutureWorld (OTC PINK: FWDG), a Delaware corporation, is a leading provider of advanced technologies and solutions to the global cannabis industry. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of cannabis related products and services, such as industrial Hemp. FutureWorld, through its subsidiaries, provides personal and professional THC and CBD test kits, pharmaceutical grade CBD oil solutions, SafeVape vaporizers, smart sensor technology, communication network, surveillance security, data analysis for smart cultivation and consultation for the industrial hemp and legal medicinal cannabis. Our wireless agricultural smart sensor networks offer precision to the agriculture, irrigation systems, and greenhouses for the global cannabis and hemp industry. FutureWorld and its subsidiaries do not grow, distribute or sell marijuana. As the only Cannabis Technology Accelerator, FutureWorld will incubate and fund leading technologies, products, and services for Cannabis industry (Industrial Hemp) for foreseeable future; bringing value to its core and its shareholders.

To request further information about FutureWorld, please email us at info@futureworldcorp.com, log onto our website at https://www.futureworldcorp.com or visit us at our Facebook page facebook.com/futureworldenergy or on Twitter @futureworldinc.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.